ReviewMycopathologia2014
Antifungal susceptibility profile of cryptic species of Aspergillus.
Review in Mycopathologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Nosocomial invasive Aspergillus calidoustus infection in a CAR-T cell-treated patient with concomitant Aspergillus fumigatus respiratory infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Identification ofJournal of clinical microbiology · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Case Report: Invasive pulmonary aspergillosis caused byFrontiers in medicine · 2026Article
- Breakthrough Tracheobronchial Aspergillosis Caused byCase reports in pulmonology · 2026Article
- Genetic analysis of common triazole resistance mechanisms in a collection ofAntimicrobial agents and chemotherapy · 2025Article
- DecipheringMicrobiology spectrum · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Potable water as a source of intermediate and borderline-resistantJournal of water and health · 2025Article
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- Evaluation of the Activity of Triazoles Against Non-Open forum infectious diseases · 2024Article
- Cytosporones Y and Z, new antifungal polyketides produced by the fungal strain Trichoderma sp. FKI-6626.The Journal of antibiotics · 2024Article
- Article
- What do We Know about Cryptic Aspergillosis?Microorganisms · 2024Review
- Metagenomic evidence for antibiotic-associated actinomycetes in the Karamay Gobi region.Frontiers in microbiology · 2024Article
- Changes in fungal taxonomy: mycological rationale and clinical implications.Clinical microbiology reviews · 2023Review
- Analysis of theAntimicrobial agents and chemotherapy · 2023Article
- Integrative Taxonomy Approach Reveals Cryptic Diversity within the Phoretic Pseudoscorpion GenusInsects · 2023Article
- A Practical Workflow for the Identification of Aspergillus, Fusarium, Mucorales by MALDI-TOF MS: Database, Medium, and Incubation Optimization.Journal of clinical microbiology · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of molecular tools has led to the description of new cryptic species among different Aspergillus species complexes. Their frequency in the clinical setting has been reported to be between 10 and 15%. The susceptibility to azoles and amphotericin B of many of these species is low, and some of them, such as Aspergillus calidoustus or Aspergillus lentulus, are considered multi-resistant. The changing epidemiology, the frequency of cryptic species, and the different susceptibility profiles make antifungal susceptibility testing an important tool to identify the optimal antifungal agent to treat the infections caused by these species.
Indexed as
Identifiers
24972670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.